Abbvie Biotechnology Ltd

Celularity Inc.

Medarex Inc.

Anthrogenesis Corporation

Steven Alan Fischkoff

Joachim Kempeni

Roberta Weiss

Jochen G Salfeld

Mark Weinberg

Rebecca S Hoffman

Subhashis Banerjee

Elliot Keith Chartash

George Richard Granneman

Lori K Taylor

Philip Yan

Daniel Edward Tracey

Anwar Murtaza

William T Barchuk

Clive E Spiegler

Xiaokui Zhang

Brian P Murphy

Robert J Hariri

Israel Lowy

James W Edinger

Uri Herzberg

Vanessa R Voskinarian-Berse

Lin Kang

Bitao Liang

Aleksandar Francki

Vladimir Jankovic

Hong-Jung Chen

Cynthia Ray

Andrea Nordberg

Keith Wilson

Han Myint

Philippe Martin

Mohamad Hussein

Michael Yellin

James Chung-Yin Yang

Provided herein are methods of using human placental stem cells in the treatment of subjects having acute kidney injury (AKI).

Use of placental stem cells in treatment of acute kidney injury

Provided herein are methods of treating acute myeloid leukemia (AML) and multiple myeloma (MM) by administering an effective amount of a cell population comprising natural killer cells, wherein the cell population comprising natural killer cells is produced by a three-stage method comprising culturing a population of hematopoietic stem or progenitor cells in media comprising stem cell mobilizing factors, e.g., three-stage methods of producing NK cells in media comprising stem cell mobilizing factors starting with hematopoietic stem or progenitor cells from cells of the placenta, for example, from placental perfusate (e.g., human placental perfusate) or other tissues, for example, umbilical cord blood or peripheral blood. Further provided herein are methods of using the NK cells produced by the three-stage methods provided herein to suppress the proliferation of acute myeloid leukemia cells. In certain embodiments, the NK cells produced by the three-stage methods described herein are used in combination with IL-2.

Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells

Methods of treating disorders in which TNF&#x3b1; activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor &#x3b1; (hTNF&#x3b1;) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF&#x3b1; (e.g., K=10M or less), a slow off rate for hTNF&#x3b1; dissociation (e.g., K=10secor less) and neutralize hTNF&#x3b1; activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.

Methods of administering anti-TNF&#x3b1; antibodies

The invention describes methods of treating erosive polyarthritis comprising administering a TNF&#x3b1; antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF&#x3b1; antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.

Use of TNF&#x3b1; inhibitor for treatment of psoriasis

Use of TNF&#x3b1; inhibitor for treatment of psoriatic arthritis

Use of TNF-alpha inhibitor for treatment of psoriasis

Methods of treating disorders in which TFN&#x3b1; activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor &#x3b1; (hTNF&#x3b1;) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF&#x3b1; (e.g., K=10M or less), a slow off rate for hTNF&#x3b1; dissociation (e.g., K=10secor less) and neutralize hTNF&#x3b1; activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.

Methods of treating individuals having sarcoidosis or a sarcoidosis-related disease or disorder using placental cells are described. Also describe are kits comprising placental stem cells or a composition thereof that can be used in methods of treating sarcoidosis or a sarcoidosis-related disease or disorder.

Treatment of sarcoidosis using placental stem cells

The present invention provides methods for treating adverse events related to immunotherapy. More specifically, the present invention provides methods for treating the enterocolitis associated with anti-CTLA-4 antibody immunotherapy.

TNF-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy

Growing community of inventors

Short Hills, NJ, United States of America

Steven Alan Fischkoff